SCHEMBL17216447

SCHEMBL17216447

Fc1cc(F)cc(CO/N=[C]\c2ccccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 4/20 0.40
▸ TACR1 P25103 2/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ GSK3B P49841 2/20 0.33
▸ BACE1 P56817 2/20 0.33
▸ MMP1 P03956 1/20 0.33
▸ MMP2 P08253 1/20 0.33
▸ MMP9 P14780 1/20 0.33
▸ MMP12 P39900 1/20 0.33
▸ AGXT P21549 2/20 0.33
▸ NPC1 O15118 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ RAB9A P51151 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ NR4A2 P43354 1/20 0.31
▸ GFER P55789 1/20 0.31
▸ MAOB P27338 3/20 0.31
▸ DHFR P00374 1/20 0.31
▸ DCPS Q96C86 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17216450 1.00 IDO1 (0.40) IDO1TACR1SMN1; SMN2GSK3BBACE1
SCHEMBL17216942 0.88 IDO1 (0.41) IDO1GSK3BBACE1MMP1MMP2
SCHEMBL17216944 0.88 IDO1 (0.41) IDO1GSK3BBACE1MMP1MMP2
SCHEMBL17216989 0.87 IDO1 (0.41) IDO1SMN1; SMN2AGXTNR4A2MAOB
SCHEMBL17218943 0.87 IDO1 (0.49) IDO1SMN1; SMN2AGXTLMNAL3MBTL1
SCHEMBL17218940 0.87 IDO1 (0.49) IDO1SMN1; SMN2AGXTLMNAL3MBTL1
SCHEMBL17216987 0.87 IDO1 (0.41) IDO1SMN1; SMN2AGXTNR4A2MAOB
SCHEMBL17218407 0.85 IDO1 (0.41) IDO1SMN1; SMN2AGXTNPC1GAA
SCHEMBL17218405 0.85 IDO1 (0.41) IDO1SMN1; SMN2AGXTNPC1GAA
SCHEMBL17219127 0.84 IDO1 (0.38) IDO1GSK3BBACE1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 IDO1 2882/4885TACR1 1033/4885SMN1; SMN2 4013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback